Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C17H25N3O |
| Molecular Weight | 287.3999 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(C1=NOC(CCN(CC)CC)=N1)C2=CC=CC=C2
InChI
InChIKey=OLTAWOVKGWWERU-UHFFFAOYSA-N
InChI=1S/C17H25N3O/c1-4-15(14-10-8-7-9-11-14)17-18-16(21-19-17)12-13-20(5-2)6-3/h7-11,15H,4-6,12-13H2,1-3H3
| Molecular Formula | C17H25N3O |
| Molecular Weight | 287.3999 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Proxazole Citrate is a spasmolytic papaverine-like agent used for functional gastrointestinal disorders in veterinary and acute renal insufficiency. In animal models, Proxazole has antitussive, antispasmodic, analgesic, anti-inflammatory, and antipyretic activities. Proxazole has veterinary uses against gastritis, infective and non-infective gastro-enteritis, urethritis, cystitis and spastic states with an inflammatory component of the smooth muscles of the digestive and genito-urinary systems. Proxazole is excreted both in feces and urine mainly as inactive metabolites.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:10:13 GMT 2025
by
admin
on
Mon Mar 31 23:10:13 GMT 2025
|
| Record UNII |
6MRD2SLE7W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
31363-09-4
Created by
admin on Mon Mar 31 23:10:13 GMT 2025 , Edited by admin on Mon Mar 31 23:10:13 GMT 2025
|
PRIMARY | |||
|
6MRD2SLE7W
Created by
admin on Mon Mar 31 23:10:13 GMT 2025 , Edited by admin on Mon Mar 31 23:10:13 GMT 2025
|
PRIMARY |